1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Garcia-Monaco RD, Chung JW, Vilgrain V, et al. Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. Br J Radiol, 2022, 95(1138): 20220179. doi: 10.1259/bjr.20220179.
|
3. |
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018, 68(2): 723-750.
|
4. |
Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol, 2017, 23(29): 5282-5294.
|
5. |
Wang Q, Zhao P, He N, et al. Combination of the gamma-glutamyltransferase-to-prealbumin ratio and other indicators may be a novel marker for predicting the prognosis of patients with hepatocellular carcinoma undergoing locoregional ablative therapies. Infect Agent Cancer, 2019, 14: 49. doi: 10.1186/s13027-019-0266-1.
|
6. |
Ke Q, Xiang F, Xiao C, et al. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization. BMC Cancer, 2021, 21(1): 1117. doi: 10.1186/s12885-021-08843-z.
|
7. |
Huo RR, Liu HT, Deng ZJ, et al. Dose-response between serum prealbumin and all-cause mortality after hepatectomy in patients with hepatocellular carcinoma. Front Oncol, 2021, 10: 596691. doi: 10.3389/fonc.2020.596691.
|
8. |
Liang L, Quan B, Wu H, et al. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. Hepatol Int, 2021, 15(2): 459-471.
|
9. |
Nakayama H, Okamura Y, Higaki T, et al. Effect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysis. J Gastroenterol, 2023, 58(2): 171-181.
|
10. |
俞巍, 张洪义, 王鹏辉. 射频消融治疗肝癌的研究进展. 中国临床医生杂志, 2021, 49(4): 385-387.
|
11. |
Liu Y, Liu L. Changes in the epidemiology of hepatocellular carcinoma in Asia. Cancers (Basel), 2022, 14(18): 4473. doi: 10.3390/cancers14184473.
|
12. |
Ren A, Li Z, Zhang X, et al. Inflammation-based prognostic scores in patients with hepatitis B virus-related hepatocellular carcinoma after liver transplantation. J Hepatocell Carcinoma, 2020, 7: 101-106.
|
13. |
Zhang LX, Lv Y, Xu AM, et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer, 2019, 19(1): 841. doi: 10.1186/s12885-019-6011-8.
|
14. |
Corti A, Franzini M, Paolicchi A, et al. Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res, 2010, 30(4): 1169-1181.
|
15. |
Fan Y, Sun Y, Man C, et al. Preoperative serum prealbumin level and adverse prognosis in patients with hepatocellular carcinoma after hepatectomy: a meta-analysis. Front Oncol, 2021, 11: 775425. doi: 10.3389/fonc.2021.775425.
|
16. |
Johnson P, Zhou Q, Dao DY, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, 2022, 19(10): 670-681.
|
17. |
Bird TG, Dimitropoulou P, Turner RM, et al. Alpha-fetoprotein detection of hepatocellular carcinoma leads to a standardized analysis of dynamic AFP to improve screening based detection. PLoS One, 2016, 11(6): e0156801. doi: 10.1371/journal.pone.0156801.
|
18. |
Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463.
|